Combinations Continue To Drive Immuno-Oncology Deal-Making
The pursuit by the industry to find novel combinations that can address more patients and more tumor types has driven overall immuno-oncology deal activity by big pharma and mid pharma companies between 2012 and 2016.
You may also be interested in...
Immuno-oncology has significant diagnostic needs including identifying patients most likely to respond to therapies. Current diagnostic approaches often fall short, due in large part to the complexity of the biology driving therapy responsiveness. As such, the biopharma industry is exploring many emerging approaches covering tumor, immune and even microbiome-related pathways and biomarkers.
The clinical potential of immuno-oncology drugs does not seem to be reflected in approaches by health technology assessment bodies, with different interpretations of data, broad labels and cost all contributing to disparate reimbursement decisions.
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.